Abatacept

Patients with rheumatoid arthritis who receive abatacept or certolizumab pegol achieve clinical remission at higher rates than those receiving active conventional therapy, according to data published in Annals of the Rheumatic Diseases.

SAN DIEGO — The future of ANCA-associated vasculitis management appears promising, as upcoming therapies will likely address current unmet needs, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

The American College of Rheumatology “strongly recommends” against the use of glucocorticoids as a first-line therapy for interstitial lung disease in patients with systemic sclerosis-associated ILD, according to newly released guidelines.

In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discussed some of the biggest challenges in treating rheumatoid arthritis, including issues with infections and other comorbidities.

For the prevention of rheumatoid arthritis to become feasible, it may be necessary to intervene as soon as possible in the pre-RA course, although the specific timing remains unclear, according to a speaker at the EULAR 2023 Congress.

DESTIN, Fla. — Complicated disease pathogenesis and a lack of FDA-approved therapies makes sarcoidosis a significant clinical challenge, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

Reactivation of double-stranded DNA viruses is an important cause of morbidity and mortality after hematopoietic stem cell transplantation.

Nearly two-thirds of patients with rheumatoid arthritis meet the criteria for at least one sleep disorder, according to data published in Arthritis Care & Research.

Therapy discontinuance and 1-year response rates for Janus kinase and interleukin-6 inhibitors are similar to those of TNF inhibitors in patients with rheumatoid arthritis, according to data published in Annals of the Rheumatic Diseases.

DESTIN, Fla. — Adjustments made to the dosing and administration of immunomodulatory drugs may not have much impact on COVID-19 vaccine immunogenicity among patients with autoimmune and inflammatory rheumatic disease, according to data.